Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia | Science Translational Medicine
Fratricide-resistant anti-CD21 CAR-T cells are effective in preclinical models of T cell acute lymphoblastic leukemia (T-ALL).
